· Published by Health Canada · Official notice
This is duplicated text of a letter from Medtronic of Canada Ltd.
Contact the company for a copy of any references, attachments or enclosures.
Notice about Health Canada advisories
May 7, 2008
To: Hospital Chief of Medical Staff
Please distribute to the relevant Departments of [Surgery; Emergency Medecine, Pharmacy, Pediatrics, Anesthesia, Geriatrics, Internal Medicine, Nursing, Dentistry, Intensive Care and/or other Departments as required] and other involved professional staff and post this NOTICE in your institution.
Subject: Medical Device Notification - Contaminated Heparin Used in Trillium® Coatings Applied to Selected Cardiopulmonary Bypass Products
Dear Health Care Professional,
This letter is to advise you that certain Trillium®Footnote 1-coated Medtronic cardiopulmonary bypass (CPB) products (e.g. oxygenators, reservoirs, pumps and tubing packs) were manufactured with heparin batches contaminated with oversulfated chondroitin sulfate (OSCS). Based upon currently available information, we have determined that Medtronic Trillium®-coated products can continue to be used in cardiopulmonary bypass procedures.
Medtronic's heparin supplier recently reported that it had provided some batches of heparin to Medtronic which were contaminated with OSCS. Medtronic has no evidence linking the use of Trillium®-coated CPB products to OSCS related adverse events. We are informing you because OSCS is not intended to be a component material of our Trillium® coating and because OSCS has been reported to cause patient adverse events when injectable formulations of contaminated heparin are given in sufficient doses. Affected Trillium®-coated products have been distributed since January 24, 2008. A listing of affected product lots can be found at medtronic.
Background
The US regulatory agency, the Food and Drug Administration (FDA), has recently received numerous adverse event reports potentially caused by systemically administered, contaminated heparin, including acute hypotension, allergic response type symptoms and death. On April 8, 2008, FDA issued an important notice to manufacturers of medical devices urging that they re-evaluate their heparin supplies using FDA-recommended test methods.
Risk Evaluation
Medtronic has evaluated the potential clinical impact that may result from the use of, or exposure to, our heparin-containing Trillium® surface coatings. Our findings have determined:
Based upon currently available information, including the factors listed above, we have determined that Medtronic Trillium®-coated products can continue to be used in cardiopulmonary bypass procedures.
Recommendations to healthcare professionals for patient care
As recommended in Health Canada's Notice to hospitals dated March 27, 2008, physicians exposing patients to heparin should continue to "monitor the patients for adverse events, particularly hypotension and signs and symptoms of hypersensitivity, and ensure that resuscitation equipment is available." Should your patients experience these symptoms, you should treat them using your standard procedures.
If you have any further questions concerning the execution of Trillium-coated CBP products notification, please contact your local Medtronic Representative or Medtronic Customer Service Representative at 1-800-268-5346, Monday - Friday, 8:00 a.m. to 5:00 p.m. EST.
This investigation is dynamic and ongoing at FDA and within Medtronic. We will continue to monitor this situation closely and advise you of significant new developments affecting Medtronic products.
Medtronic Carmeda®-coated CPB products also contain heparin. A separate communication provides information pertaining to Medtronic's Carmeda®-coated products.
Medtronic of Canada Ltd.
6733 Kitimat Rd
Mississauga ON, L5N 1W3
Phone: 905-826-6020
Fax: 905-826-6620
Toll Free: 800-268-5346
Any suspected adverse reaction can also be reported to:
Health Products and Food Branch Inspectorate
HEALTH CANADA
Address Locator: 2003D
Ottawa, Ontario K1A 0K9
Tel: The Inspectorate Hotline 1-800-267-9675
The Reporting Form and Guidelines can be obtained from the Health Canada web site.
For other inquiries related to this communication, please contact Health Canada at:
Marketed Health Products Directorate (MHPD)
email: MHPD_DPSC@hc-sc.gc.ca
Tel.: 613-954-6522
Fax.: 613-952-7738
Health Canada has been notified of this action.
We understand that you depend on us to support your practice by reliably providing the highest quality medical devices. We apologize for the inconvenience caused by this Medical Device notification.
Sincerely,
Original signed by
Jon Olsen
Director, Sales & Marketing
Cardiovascular Surgery Products
Medtronic of Canada Ltd.
Technology license under agreement from BioInteractions, Limited, United Kingdom